Given the unique binding profile of pasireotide and experience from studies in healthy volunteers, incretin-based therapies (dipeptidyl peptidase 4 [DPP-4] inhibitors and glucagon-like peptide 1 [GLP-1] receptor agonists) may be useful for managing hyperglycemia during pasireotide treatment [17, 20, 21]. This evidence concerns the gene DPP4 and Hyperglycemia.